Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England

Open Access

Peer-reviewed

Research Article

Chee-Fu Yung ,

* E-mail: chee_fu_yung@ttsh.com.sg

Affiliations Department of Clinical Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore, Singapore, Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, London, United Kingdom
⨯
Nick Andrews,

Affiliation Statistics Unit, Health Protection Services, Colindale, Health Protection Agency, London, United Kingdom
⨯
Katja Hoschler,

Affiliation Respiratory Virus Unit, Virus Reference Department, Microbiology Services, Colindale, Health Protection Agency, London, United Kingdom
⨯
Elizabeth Miller

Affiliation Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, London, United Kingdom
⨯

Reader Comments (0)

Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Vaccination and immunization
Is the Subject Area "Vaccination and immunization" applicable to this article?

Thanks for your feedback.
Vaccines
Is the Subject Area "Vaccines" applicable to this article?

Thanks for your feedback.
Pandemics
Is the Subject Area "Pandemics" applicable to this article?

Thanks for your feedback.
H1N1
Is the Subject Area "H1N1" applicable to this article?

Thanks for your feedback.
Influenza
Is the Subject Area "Influenza" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
Antigens
Is the Subject Area "Antigens" applicable to this article?

Thanks for your feedback.